What type of study is this?

October 2, 2025

Supplementary Figure S4 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

View Full Paper

Ask AI

Bookmark

Patients exhibited significant percentage changes in target lesion size following treatment with nelitolimod.
Changes in target lesion size reached notable levels, highlighting the effectiveness of the combined treatment regimen.
An open-label, multicenter approach ensured diverse patient representation and robust findings.
The findings emphasize the potential for nelitolimod in advancing treatment options for patients with advanced melanoma.

Implication

Open-label study finds significant tumor size changes with nelitolimod and pembrolizumab, indicating potential efficacy.

Abstract

Figure S4 shows best percentage changes from baseline in target lesion size for patients treated with nelitolimod 2 mg or 8 mg plus pembrolizumab 200 mg. The plot illustrates the depth of tumor response across both dosing groups.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ribas et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a219c6 https://doi.org/10.1158/1078-0432.30255665

View Full Paper

Ask AI

Bookmark

Implication

Open-label study finds significant tumor size changes with nelitolimod and pembrolizumab, indicating potential efficacy.

Supplementary Figure S4 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S4 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Key Points

Implication

Abstract

Discussion

Cite This Study